Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 463

1.

RORγ is a targetable master regulator of cholesterol biosynthesis in a cancer subtype.

Cai D, Wang J, Gao B, Li J, Wu F, Zou JX, Xu J, Jiang Y, Zou H, Huang Z, Borowsky AD, Bold RJ, Lara PN, Li JJ, Chen X, Lam KS, To KF, Kung HJ, Fiehn O, Zhao R, Evans RM, Chen HW.

Nat Commun. 2019 Oct 11;10(1):4621. doi: 10.1038/s41467-019-12529-3.

PMID:
31604910
2.

VSTM2A suppresses colorectal cancer and antagonizes Wnt signaling receptor LRP6.

Dong Y, Zhang Y, Kang W, Wang G, Chen H, Higashimori A, Nakatsu G, Go M, Tong JH, Zheng S, To KF, Sung JJ, Yang X, Ng SS, Yu J.

Theranostics. 2019 Aug 21;9(22):6517-6531. doi: 10.7150/thno.34989. eCollection 2019.

3.

"Interchangeability" of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy.

Torlakovic E, Lim HJ, Adam J, Barnes P, Bigras G, Chan AWH, Cheung CC, Chung JH, Couture C, Fiset PO, Fujimoto D, Han G, Hirsch FR, Ilie M, Ionescu D, Li C, Munari E, Okuda K, Ratcliffe MJ, Rimm DL, Ross C, Røge R, Scheel AH, Soo RA, Swanson PE, Tretiakova M, To KF, Vainer GW, Wang H, Xu Z, Zielinski D, Tsao MS.

Mod Pathol. 2019 Aug 5. doi: 10.1038/s41379-019-0327-4. [Epub ahead of print] Review.

PMID:
31383961
4.

WITER: a powerful method for estimation of cancer-driver genes using a weighted iterative regression modelling background mutation counts.

Jiang L, Zheng J, Kwan JSH, Dai S, Li C, Li MJ, Yu B, To KF, Sham PC, Zhu Y, Li M.

Nucleic Acids Res. 2019 Jul 9. pii: gkz566. doi: 10.1093/nar/gkz566. [Epub ahead of print]

PMID:
31287869
5.

Eukaryotic elongation factor-2 kinase expression is an independent prognostic factor in colorectal cancer.

Ng TH, Sham KWY, Xie CM, Ng SSM, To KF, Tong JHM, Liu WYZ, Zhang L, Chan MTV, Wu WKK, Cheng CHK.

BMC Cancer. 2019 Jul 2;19(1):649. doi: 10.1186/s12885-019-5873-0.

6.

Targeting the Oncogenic FGF-FGFR Axis in Gastric Carcinogenesis.

Zhang J, Tang PMK, Zhou Y, Cheng ASL, Yu J, Kang W, To KF.

Cells. 2019 Jun 25;8(6). pii: E637. doi: 10.3390/cells8060637. Review.

7.

A comparability study of immunohistochemical assays for PD-L1 expression in hepatocellular carcinoma.

Shi L, Zhang SJ, Chen J, Lu SX, Fan XJ, Tong JH, Chow C, Tin EK, Chan SL, Chong CC, Lai PB, To KF, Wong N, Chan AW.

Mod Pathol. 2019 Jun 23. doi: 10.1038/s41379-019-0307-8. [Epub ahead of print]

PMID:
31231126
8.

Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.

Liu M, Zhou J, Liu X, Feng Y, Yang W, Wu F, Cheung OK, Sun H, Zeng X, Tang W, Mok MTS, Wong J, Yeung PC, Lai PBS, Chen Z, Jin H, Chen J, Chan SL, Chan AWH, To KF, Sung JJY, Chen M, Cheng AS.

Gut. 2019 May 10. pii: gutjnl-2018-317257. doi: 10.1136/gutjnl-2018-317257. [Epub ahead of print]

PMID:
31076403
9.

TTPAL Promotes Colorectal Tumorigenesis by Stabilizing TRIP6 to Activate Wnt/β-Catenin Signaling.

Gou H, Liang JQ, Zhang L, Chen H, Zhang Y, Li R, Wang X, Ji J, Tong JH, To KF, Sung JJY, Chan FKL, Fang JY, Yu J.

Cancer Res. 2019 Jul 1;79(13):3332-3346. doi: 10.1158/0008-5472.CAN-18-2986. Epub 2019 Apr 24.

PMID:
31018940
10.

PRRX-NCOA1/2 rearrangement characterizes a distinctive fibroblastic neoplasm.

Lacambra MD, Weinreb I, Demicco EG, Chow C, Sung YS, Swanson D, To KF, Wong KC, Antonescu CR, Dickson BC.

Genes Chromosomes Cancer. 2019 Oct;58(10):705-712. doi: 10.1002/gcc.22762. Epub 2019 Apr 30.

PMID:
31008539
11.

The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung.

Chan AW, Chau SL, Tong JH, Chow C, Kwan JSH, Chung LY, Lung RW, Tong CY, Tin EK, Law PP, Law WT, Ng CSH, Wan IYP, Mok TSK, To KF.

J Thorac Oncol. 2019 Jul;14(7):1213-1222. doi: 10.1016/j.jtho.2019.03.021. Epub 2019 Apr 9.

PMID:
30978501
12.

Mechanotransduction and Cytoskeleton Remodeling Shaping YAP1 in Gastric Tumorigenesis.

Zhang J, Zhou Y, Tang PMK, Cheng ASL, Yu J, To KF, Kang W.

Int J Mol Sci. 2019 Mar 29;20(7). pii: E1576. doi: 10.3390/ijms20071576. Review.

13.

Correction: Hsa-miRNA-765 as a Key Mediator for Inhibiting Growth, Migration and Invasion in Fulvestrant-Treated Prostate Cancer.

Leung YK, Chan QK, Ng CF, Ma FM, Tse HM, To KF, Maranchie J, Ho SM, Lau KM.

PLoS One. 2019 Mar 18;14(3):e0214184. doi: 10.1371/journal.pone.0214184. eCollection 2019.

14.

Aberrant enhancer hypomethylation contributes to hepatic carcinogenesis through global transcriptional reprogramming.

Xiong L, Wu F, Wu Q, Xu L, Cheung OK, Kang W, Mok MT, Szeto LLM, Lun CY, Lung RW, Zhang J, Yu KH, Lee SD, Huang G, Wang CM, Liu J, Yu Z, Yu DY, Chou JL, Huang WH, Feng B, Cheung YS, Lai PB, Tan P, Wong N, Chan MW, Huang TH, Yip KY, Cheng AS, To KF.

Nat Commun. 2019 Jan 18;10(1):335. doi: 10.1038/s41467-018-08245-z.

15.

Targeting the miR-630/YAP1/ERK feedback loop in epidermal growth factor receptor-mutated lung adenocarcinomas.

Zhang J, Cheng ASL, Yu J, To KF, Kang W.

J Thorac Dis. 2018 Nov;10(Suppl 33):S4017-S4020. doi: 10.21037/jtd.2018.10.16. No abstract available.

16.

An inflammatory-CCRK circuitry drives mTORC1-dependent metabolic and immunosuppressive reprogramming in obesity-associated hepatocellular carcinoma.

Sun H, Yang W, Tian Y, Zeng X, Zhou J, Mok MTS, Tang W, Feng Y, Xu L, Chan AWH, Tong JH, Cheung YS, Lai PBS, Wang HKS, Tsang SW, Chow KL, Hu M, Liu R, Huang L, Yang B, Yang P, To KF, Sung JJY, Wong GLH, Wong VWS, Cheng ASL.

Nat Commun. 2018 Dec 6;9(1):5214. doi: 10.1038/s41467-018-07402-8.

17.

Mismatch repair deficiency is implicated in carcinoma arising from ovarian teratoma.

Cheung AH, Chow C, Yu MY, Law WW, Law PP, Choi PC, Kang W, To KF.

Pathology. 2019 Jan;51(1):67-73. doi: 10.1016/j.pathol.2018.09.061. Epub 2018 Nov 28.

PMID:
30502217
18.

Oncogenes expand during evolution to withstand somatic amplification.

Wang X, Li X, Zhang L, Wong SH, Wang MHT, Tse G, Dai RZW, Nakatsu G, Coker OO, Chen Z, Ko H, Chan JYK, Liu T, Cheng CHK, Cheng ASL, To KF, Plewczynski D, Sung JJY, Yu J, Gin T, Chan MTV, Wu WKK.

Ann Oncol. 2018 Nov 1;29(11):2254-2260. doi: 10.1093/annonc/mdy397.

PMID:
30204835
19.

EXOSC4 functions as a potential oncogene in development and progression of colorectal cancer.

Pan Y, Tong JHM, Kang W, Lung RWM, Chak WP, Chung LY, Wu F, Li H, Yu J, Chan AWH, To KF.

Mol Carcinog. 2018 Dec;57(12):1780-1791. doi: 10.1002/mc.22896. Epub 2018 Sep 21.

PMID:
30155936
20.

The Clinical Value of PELP1 for Breast Cancer: A Comparison with Multiple Cancers and Analysis in Breast Cancer Subtypes.

Wang X, Tsang JYS, Lee MA, Ni YB, Tong JH, Chan SK, Cheung SY, To KF, Tse GM.

Cancer Res Treat. 2019 Apr;51(2):706-717. doi: 10.4143/crt.2018.316. Epub 2018 Aug 23.

21.

FGF18, a prominent player in FGF signaling, promotes gastric tumorigenesis through autocrine manner and is negatively regulated by miR-590-5p.

Zhang J, Zhou Y, Huang T, Wu F, Pan Y, Dong Y, Wang Y, Chan AKY, Liu L, Kwan JSH, Cheung AHK, Wong CC, Lo AKF, Cheng ASL, Yu J, Lo KW, Kang W, To KF.

Oncogene. 2019 Jan;38(1):33-46. doi: 10.1038/s41388-018-0430-x. Epub 2018 Aug 6.

22.

RASAL2 promotes tumor progression through LATS2/YAP1 axis of hippo signaling pathway in colorectal cancer.

Pan Y, Tong JHM, Lung RWM, Kang W, Kwan JSH, Chak WP, Tin KY, Chung LY, Wu F, Ng SSM, Mak TWC, Yu J, Lo KW, Chan AWH, To KF.

Mol Cancer. 2018 Jul 23;17(1):102. doi: 10.1186/s12943-018-0853-6.

23.

Latest development of liquid biopsy.

Cheung AH, Chow C, To KF.

J Thorac Dis. 2018 Jun;10(Suppl 14):S1645-S1651. doi: 10.21037/jtd.2018.04.68. Review.

24.

Loss of tumor suppressor IGFBP4 drives epigenetic reprogramming in hepatic carcinogenesis.

Lee YY, Mok MT, Kang W, Yang W, Tang W, Wu F, Xu L, Yan M, Yu Z, Lee SD, Tong JHM, Cheung YS, Lai PBS, Yu DY, Wang Q, Wong GLH, Chan AM, Yip KY, To KF, Cheng ASL.

Nucleic Acids Res. 2018 Sep 28;46(17):8832-8847. doi: 10.1093/nar/gky589.

25.
26.

Enhanced Cancer Immunotherapy with Smad3-Silenced NK-92 Cells.

Wang QM, Tang PM, Lian GY, Li C, Li J, Huang XR, To KF, Lan HY.

Cancer Immunol Res. 2018 Aug;6(8):965-977. doi: 10.1158/2326-6066.CIR-17-0491. Epub 2018 Jun 18.

27.

Granulin epithelin precursor promotes colorectal carcinogenesis by activating MARK/ERK pathway.

Pan Y, Cheung ST, Tong JHM, Tin KY, Kang W, Lung RWM, Wu F, Li H, Ng SSM, Mak TWC, To KF, Chan AWH.

J Transl Med. 2018 Jun 4;16(1):150. doi: 10.1186/s12967-018-1530-7.

28.

Specific targeting of point mutations in EGFR L858R-positive lung cancer by CRISPR/Cas9.

Cheung AH, Chow C, Zhang J, Zhou Y, Huang T, Ng KC, Or TC, Yao YY, Dong Y, Fung JM, Xiong L, Chan AK, Lung WR, Kang W, To KF.

Lab Invest. 2018 Jul;98(7):968-976. doi: 10.1038/s41374-018-0056-1. Epub 2018 May 10.

29.

Assessment of programmed cell death ligand-1 expression by 4 diagnostic assays and its clinicopathological correlation in a large cohort of surgical resected non-small cell lung carcinoma.

Chan AWH, Tong JHM, Kwan JSH, Chow C, Chung LY, Chau SL, Lung RWM, Ng CSH, Wan IYP, Mok TSK, To KF.

Mod Pathol. 2018 Sep;31(9):1381-1390. doi: 10.1038/s41379-018-0053-3. Epub 2018 Apr 30.

30.

PIEZO1 functions as a potential oncogene by promoting cell proliferation and migration in gastric carcinogenesis.

Zhang J, Zhou Y, Huang T, Wu F, Liu L, Kwan JSH, Cheng ASL, Yu J, To KF, Kang W.

Mol Carcinog. 2018 Sep;57(9):1144-1155. doi: 10.1002/mc.22831. Epub 2018 May 2.

PMID:
29683214
31.

Emerging roles of Hippo signaling in inflammation and YAP-driven tumor immunity.

Zhou Y, Huang T, Zhang J, Cheng ASL, Yu J, Kang W, To KF.

Cancer Lett. 2018 Jul 10;426:73-79. doi: 10.1016/j.canlet.2018.04.004. Epub 2018 Apr 11. Review.

PMID:
29654891
32.

The physiological role of Motin family and its dysregulation in tumorigenesis.

Huang T, Zhou Y, Zhang J, Cheng ASL, Yu J, To KF, Kang W.

J Transl Med. 2018 Apr 12;16(1):98. doi: 10.1186/s12967-018-1466-y. Review.

33.

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742).

Ma BBY, Lim WT, Goh BC, Hui EP, Lo KW, Pettinger A, Foster NR, Riess JW, Agulnik M, Chang AYC, Chopra A, Kish JA, Chung CH, Adkins DR, Cullen KJ, Gitlitz BJ, Lim DW, To KF, Chan KCA, Lo YMD, King AD, Erlichman C, Yin J, Costello BA, Chan ATC.

J Clin Oncol. 2018 May 10;36(14):1412-1418. doi: 10.1200/JCO.2017.77.0388. Epub 2018 Mar 27. Erratum in: J Clin Oncol. 2018 Aug 1;36(22):2360.

34.

CREPT facilitates colorectal cancer growth through inducing Wnt/β-catenin pathway by enhancing p300-mediated β-catenin acetylation.

Zhang Y, Wang S, Kang W, Liu C, Dong Y, Ren F, Wang Y, Zhang J, Wang G, To KF, Zhang X, Sung JJ, Chang Z, Yu J.

Oncogene. 2018 Jun;37(26):3485-3500. doi: 10.1038/s41388-018-0161-z. Epub 2018 Mar 22.

35.

Genomic analysis of liver cancer unveils novel driver genes and distinct prognostic features.

Li X, Xu W, Kang W, Wong SH, Wang M, Zhou Y, Fang X, Zhang X, Yang H, Wong CH, To KF, Chan SL, Chan MTV, Sung JJY, Wu WKK, Yu J.

Theranostics. 2018 Feb 12;8(6):1740-1751. doi: 10.7150/thno.22010. eCollection 2018.

36.

The role of human papillomavirus in laryngeal cancer in Southern China.

Lam EWH, Chan MMH, Wai CKC, Ngai CM, Chen Z, Wong MCS, Yeung ACM, Tong JHM, Chan ABW, To KF, Chan PKS.

J Med Virol. 2018 Jun;90(6):1150-1159. doi: 10.1002/jmv.25058. Epub 2018 Mar 6.

PMID:
29446476
37.

miR-375 is involved in Hippo pathway by targeting YAP1/TEAD4-CTGF axis in gastric carcinogenesis.

Kang W, Huang T, Zhou Y, Zhang J, Lung RWM, Tong JHM, Chan AWH, Zhang B, Wong CC, Wu F, Dong Y, Wang S, Yang W, Pan Y, Chak WP, Cheung AHK, Pang JCS, Yu J, Cheng ASL, To KF.

Cell Death Dis. 2018 Jan 24;9(2):92. doi: 10.1038/s41419-017-0134-0.

38.

A Novel Feeder-free System for Mass Production of Murine Natural Killer Cells In Vitro.

Tang PM, Tang PC, Chung JY, Hung JSC, Wang QM, Lian GY, Sheng J, Huang XR, To KF, Lan HY.

J Vis Exp. 2018 Jan 9;(131). doi: 10.3791/56785.

PMID:
29364233
39.

GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer.

Ni YB, Tsang JYS, Shao MM, Chan SK, Cheung SY, Tong J, To KF, Tse GM.

Breast Cancer Res Treat. 2018 May;169(1):25-32. doi: 10.1007/s10549-017-4645-2. Epub 2018 Jan 16.

PMID:
29340880
40.

Molecular and functional characterization of tumor-induced factor (TIF): Hamster homolog of CXCL3 (GROγ) displays tumor suppressive activity.

Jin L, Li ZF, Wang DK, Sun M, Qi W, Ma Q, Zhang L, Chu C, Chan EYM, Lee SST, Wise H, To KF, Shi Y, Zhou N, Cheung WT.

Cytokine. 2018 Feb;102:62-75. doi: 10.1016/j.cyto.2017.12.019. Epub 2017 Dec 23.

PMID:
29276973
41.

SRGAP1, a crucial target of miR-340 and miR-124, functions as a potential oncogene in gastric tumorigenesis.

Huang T, Zhou Y, Zhang J, Wong CC, Li W, Kwan JSH, Yang R, Chan AKY, Dong Y, Wu F, Zhang B, Cheung AHK, Wu WKK, Cheng ASL, Yu J, Wong N, Kang W, To KF.

Oncogene. 2018 Mar;37(9):1159-1174. doi: 10.1038/s41388-017-0029-7. Epub 2017 Dec 13.

42.

EBV-encoded miRNAs target ATM-mediated response in nasopharyngeal carcinoma.

Lung RW, Hau PM, Yu KH, Yip KY, Tong JH, Chak WP, Chan AW, Lam KH, Lo AK, Tin EK, Chau SL, Pang JC, Kwan JS, Busson P, Young LS, Yap LF, Tsao SW, To KF, Lo KW.

J Pathol. 2018 Apr;244(4):394-407. doi: 10.1002/path.5018. Epub 2018 Feb 16.

43.

Genomic profiles of nasopharyngeal carcinoma: The importance of histological subtyping and Epstein-Barr virus in situ assays.

Lui VWY, To KF, Lo KW.

Cancer. 2018 Jan 15;124(2):434-435. doi: 10.1002/cncr.31131. Epub 2017 Nov 22. No abstract available.

44.

The proto-oncogene tyrosine protein kinase Src is essential for macrophage-myofibroblast transition during renal scarring.

Tang PM, Zhou S, Li CJ, Liao J, Xiao J, Wang QM, Lian GY, Li J, Huang XR, To KF, Ng CF, Chong CC, Ma RC, Lee TL, Lan HY.

Kidney Int. 2018 Jan;93(1):173-187. doi: 10.1016/j.kint.2017.07.026. Epub 2017 Oct 14.

PMID:
29042082
45.

The oncogenic role of Epstein-Barr virus-encoded microRNAs in Epstein-Barr virus-associated gastric carcinoma.

Zhang J, Huang T, Zhou Y, Cheng ASL, Yu J, To KF, Kang W.

J Cell Mol Med. 2018 Jan;22(1):38-45. doi: 10.1111/jcmm.13354. Epub 2017 Oct 9. Review.

46.

Epstein-Barr virus-driven promoter hypermethylated genes in gastric cancer.

Yu J, To KF, Liang QY.

Hong Kong Med J. 2017 Aug;23 Suppl 5(4):17-22. No abstract available.

47.

Human papillomavirus infection and squamous cell carcinoma in Hong Kong: a case-control study.

Chan PK, To KF, Tsang SH, Lau CH, Kwong WH, Chan YH.

Hong Kong Med J. 2017 Aug;23 Suppl 5(4):8-11. No abstract available.

48.

Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy.

Zhou J, Liu M, Sun H, Feng Y, Xu L, Chan AWH, Tong JH, Wong J, Chong CCN, Lai PBS, Wang HK, Tsang SW, Goodwin T, Liu R, Huang L, Chen Z, Sung JJ, Chow KL, To KF, Cheng AS.

Gut. 2018 May;67(5):931-944. doi: 10.1136/gutjnl-2017-314032. Epub 2017 Sep 22.

49.

The CCCTC-binding factor (CTCF)-forkhead box protein M1 axis regulates tumour growth and metastasis in hepatocellular carcinoma.

Zhang B, Zhang Y, Zou X, Chan AW, Zhang R, Lee TK, Liu H, Lau EY, Ho NP, Lai PB, Cheung YS, To KF, Wong HK, Choy KW, Keng VW, Chow LM, Chan KK, Cheng AS, Ko BC.

J Pathol. 2017 Dec;243(4):418-430. doi: 10.1002/path.4976. Epub 2017 Oct 27.

50.

Defective lysosomal clearance of autophagosomes and its clinical implications in nonalcoholic steatohepatitis.

Wang X, Zhang X, Chu ESH, Chen X, Kang W, Wu F, To KF, Wong VWS, Chan HLY, Chan MTV, Sung JJY, Wu WKK, Yu J.

FASEB J. 2018 Jan;32(1):37-51. doi: 10.1096/fj.201601393R. Epub 2017 Aug 25.

PMID:
28842428

Supplemental Content

Support Center